Skip to main content

Table 1 Prognostic multigene signatures in breast cancer commercially available or in commercial development

From: Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction

Signature MammaPrint [51, 59] Oncotype DX [52] Theros/MGI [53, 5658] MapQuant DX/simplified [55] Veridex 76-gene [54]
Commercially available/Provider Yes/Agendia BV (Amsterdam, The Netherlands) Yes/Genomic Health (Redwood City, CA, USA) Yes/bioTheranostics, Inc.(San Diego, CA, USA) Yes/Ipsogen Inc. (Stamford, CT, USA) No/Johnson & Johnson (New Brunswick, NJ, USA)
Study population ER+ and ER-, N0, <5 cm diameter, age <55 years ER+, N0, TAM treated ER+, N0 ER+ and ER-, N0 and N+ ER+ and ER-
Assay 70-gene signature 21-gene Recurrence Score 2-gene HOXB13:IL17R/molecular-grade index 97-gene signature/8-gene PCR 76-gene signature
Platform Microarray (Agilent Technologies, Inc., Santa Clara, CA, USA) RT-PCR RT-PCR Microarray (Affymetrix, Santa Clara, CA, USA)/RT-PCR Microarray (Affymetrix)
Tissue type Frozen or stabilized mRNA FFPE FFPE Frozen/FFPE Frozen
Prognostic value in other populations Age 55-70 years, 1-3 N+, N0 and N+, HER2+ ER+ and 1-3 N+, ER+ postmenopausal receiving aromatase inhibitors - ER+ receiving aromatase inhibitors  
Predictive value Neoadjuvant and adjuvant CT (poor signature) Neoadjuvant and adjuvant CT [71] (high-RS), response to TAM (low-RS) Resistance to TAM (high-ratio) Response to neoadjuvant CT (high-risk) Response to TAM (high-risk patients)
Indication Prognostic in N0, <5 cm diameter, stage I/II BC, Prediction of recurrence risk in ER+ and N0 BC treated with TAM Prognostic in ER+ BC, prediction of response to TAM Molecular grading, for ER+, histological grade II BC Prognostic in ER+ BC
Level of evidence III II III III III
FDA approval Yes No No No No
Randomized trial MINDACT TAILORx - - -
Availability Europe and USA Europe and USA USA Europe -
  1. BC, breast cancer; CT, chemotherapy; ER; estrogen receptor status (+ or -); FDA, US Food and Drug Administration; FFPE, formalin-fixed paraffin-embedded; HER2, human epidermal growth factor receptor 2; HOXB13, homeobox 13; IL-17BR, interleukin-17B receptor; MGI, molecular grade index; MINDACT, Microarray In Node-negative and 1-3 positive lymph-node Disease may Avoid ChemoTherapy; N+, lymph node-positive; N0, lymph node-negative; PCR, polymerase chain reaction; RS, recurrence score; RT-PCR, reverse transcriptase-polymerase chain reaction; TAILORx, Trial Assigning IndividuaLized Options for Treatment Rx; TAM, tamoxifen.